Ítem
Acceso Abierto
Enfermedad hemato-oncológica y factores asociados con niveles subterapéuticos de vancomicina en un hospital de alta complejidad
dc.contributor.advisor | Castañeda Luquerna, Aurora Ximena | |
dc.contributor.advisor | Ramírez Villamizar, Johanna Amparo | |
dc.creator | Parra Hernández, Diana Sofía | |
dc.creator | Peña Parra, Andrés Felipe | |
dc.creator.degree | Especialista en Medicina Interna | |
dc.date.accessioned | 2017-05-15T12:56:28Z | |
dc.date.available | 2017-05-15T12:56:28Z | |
dc.date.created | 2017-05-10 | |
dc.date.issued | 2017 | |
dc.description | Introducción: La medición de niveles séricos valle de vancomicina es recomendada por las guías actuales para la monitorización del tratamiento, esperando valores entre 15-20mg/L en infección severas. Existen distintas variables que se asocian a no alcanzar niveles efectivos las cuales se buscan determinar en este estudio. Materiales y Métodos: Estudio retrospectivo de casos y controles en adultos hospitalizados a los que se les realizó niveles séricos de vancomicina en el período de enero de 2013 a diciembre de 2014. El objetivo de este estudio fue determinar los factores asociados con niveles séricos subterapéuticos, su relación con la enfermedad hemato-oncológica y otras variables farmacocinéticas. Resultados: Se analizaron 857 historias clínicas, de las cuales 377 cumplieron los criterios de inclusión. Se seleccionaron de forma aleatoria no emparejada 92 casos y 202 controles en una relación 1:2. Se encontraron cuatro variables estadísticamente significativas entre ellas, enfermedad hemato-oncológica OR 2,12; 95% IC 1,53-4,88; P=0,004, índice de masa corporal mayor de 23 OR 1,15; 95% IC 1,07-1,2; P=0,000, edad mayor de 75 años OR 0,96; 95% IC 0,93-0,96; P=0,000 y creatinina mayor 0,7mg/dL OR 0,08; 95% IC 0,01-0,11; P= 0,000. Conclusiones: La enfermedad hemato-oncológica y el índice de masa corporal son factores asociados a la presencia de niveles subterapéuticos de vancomicina en sangre estadísticamente significativos. Mientras que la edad mayor a 75 años y los valores de creatinina mayores a 0,7mg/dL fueron factores protectores. | spa |
dc.description.abstract | Introduction: Measurement of serum levels of vancomycin is recommended by currentguidelines for therapeutic drug monitor with target values between 15-20mg / L in severeinfections. There are several variables associated with not reaching effective levels thatare sought to be determined in this study. Materials and Methods: Retrospective study of cases and controls in hospitalized adultswho underwent serum vancomycin levels from January 2013 to December 2014. Theobjective of this study was to determine the factors associated with subtherapeutic serumlevels, its relationship with hemato-oncologic disease and other pharmacokineticvariables. Results: A total of 857 clinical records were analyzed, of which 377 met the inclusioncriteria. We randomly selected 92 cases and 202 unmatched controls in a 1: 2 ratio. Fourstatistically significant variables were found, including hemato-oncologic disease OR2. 12; 95% CI 1. 53-4. 88; P = 0. 004, body mass index greater than 23 OR 1. 15; 95% CI1. 07-1. 2; P = 0. 000, age less than 75 years OR 0. 96; 95% CI 0. 93-0. 96; P = 0. 000 andlower creatinine values 0. 7mg / dL OR 0. 08; 95% CI 0. 01-0. 11; P = 0. 000. Conclusions: Hemato-oncologic disease and body mass index are factors associated withthe presence of statistically significant subtherapeutic levels of vancomycin in blood. While age greater than 75 years and creatinine values above 0. 7mg / dL were protectivefactors. | eng |
dc.format.mimetype | application/pdf | |
dc.identifier.doi | https://doi.org/10.48713/10336_13376 | |
dc.identifier.uri | http://repository.urosario.edu.co/handle/10336/13376 | |
dc.language.iso | spa | |
dc.publisher | Universidad del Rosario | spa |
dc.publisher.department | Facultad de Medicina | spa |
dc.publisher.program | Especialización en Medicina Interna | spa |
dc.rights.accesRights | info:eu-repo/semantics/openAccess | |
dc.rights.acceso | Abierto (Texto completo) | spa |
dc.rights.licencia | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | spa |
dc.source.bibliographicCitation | Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Blázquez J. Antibiotics and antibiotic resistance: A bitter fight against evolution. Int J Med Microbiol. Elsevier GmbH.; 2013;303(6– 7):293–7. | |
dc.source.bibliographicCitation | Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1(Suppl 1):S35–9. | |
dc.source.bibliographicCitation | Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285–92. | |
dc.source.bibliographicCitation | Reardon J, Lau TTY, Ensom MHH. Vancomycin Loading Doses: A Systematic Review. Ann Pharmacother. 2015;29(5):557–65. | |
dc.source.bibliographicCitation | Hyuk M, Hwa Y, Lee S, Hoon S, Kim J. Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin. Clin Chim Acta. Elsevier B.V.; 2017;465:106–11. | |
dc.source.bibliographicCitation | Levine DP. Vancomycin : A History. Clin Infect Dis. 2006;48201:5–12. | |
dc.source.bibliographicCitation | Moellering RC. Vancomycin : A 50-Year Reassessment. Clin Infect Dis. 2006;42(Suppl 1):3–4. | |
dc.source.bibliographicCitation | Bruniera R. The use of vancomycin with its therapeutic and adverse effects : a review. Eur Rev Med Pharmacol Sci. 2015;19:694–700 | |
dc.source.bibliographicCitation | Mouton JW. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. 2014. 1-467 p. | |
dc.source.bibliographicCitation | Bosso J a., Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob Agents Chemother. 2011;55(12):5475–9. | |
dc.source.bibliographicCitation | Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–44. | |
dc.source.bibliographicCitation | Leong J, Boro M, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Heal Pharm. 2011;68(119):599–603. | |
dc.source.bibliographicCitation | Boulamery A, Bruguerolle B, Simon N. Vancomycin A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet 2012; 2012;51(1):1–13. | |
dc.source.bibliographicCitation | Buelga DS, Fernandez M, Herrera E V, Dominguez-gil A. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies. Antimicrob Agents Chemother. 2005;49(12):4934–41. | |
dc.source.bibliographicCitation | Soni SS, Ronco C, Katz N, Cruz DN. Early diagnosis of acute kidney injury: The promise of novel biomarkers. Blood Purif. 2009;28(3):165–74. | |
dc.source.bibliographicCitation | Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust. 2009;191(7):368–73. | |
dc.source.bibliographicCitation | Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65(12):2658–65. | |
dc.source.bibliographicCitation | Robinson JO, Phillips M, Christiansen KJ, Pearson JC, Coombs GW, Murray RJ. Knowing prior methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization status increases the empirical use of glycopeptides in MRSA bacteraemia and may decrease mortality. Clin Microbiol Infect. European Society of Clinical Infectious Diseases; 2014;20(6):530–5. | |
dc.source.bibliographicCitation | Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32(6):848–52 | |
dc.source.bibliographicCitation | Matzke G, McGory R, Halstenson, Charles Keane W. Pharmacokinetics of Vancomycin in Patients with Various Degrees of Renal Function. Antimicrob Agents Chemother. 1984;25(5):433–7. | |
dc.source.bibliographicCitation | Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):1. | |
dc.source.bibliographicCitation | Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013;39(7):1247–52. | |
dc.source.bibliographicCitation | Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. Elsevier; 2013;19(3):365–80. | |
dc.source.bibliographicCitation | Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Heal Pharm. 2009;66(1):82–98. | |
dc.source.bibliographicCitation | Fernandez de gatta M, Buelga DS, Sánchez A, Dominguez-gil A, Garcia MJ. Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic / Pharmacodynamic Analysis. Clin Pharmacokinet. 2009;48(4):273–80. | |
dc.source.bibliographicCitation | Minkute R, Briedis V, Steponavičiute R, Vitkauskiene a., Mačiulaitis R. Augmented renal clearance - An evolving risk factor to consider during the treatment with vancomycin. J Clin Pharm Ther. 2013;38(6):462–7. | |
dc.source.bibliographicCitation | Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(12):1536–42. | |
dc.source.bibliographicCitation | Steinmetz T, Eliakim-Raz N, Goldberg E, Leibovici L, Yahav D. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect. Elsevier Ltd; 2015;21(7):665–73. | |
dc.source.bibliographicCitation | Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: Systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(1):17–24. | |
dc.source.bibliographicCitation | Howden BP, Ward PB, Charles PGP, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38(4):521–8. | |
dc.source.bibliographicCitation | Romano S, Calvo M V, Caballero D, Lanao JM. Population pharmacokinetics of amikacin in patients with. J Antimicrob Chemother. 1999;44:235–42. | |
dc.source.bibliographicCitation | Haeseker MB, Croes S, Neef C, Bruggeman CA, Stolk LML, Verbon A. Vancomycin Dosing in Neutropenic Patients. PLoS One. 2014;9(11):e112008 | |
dc.source.bibliographicCitation | Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, et al. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. Med Mal Infect. Elsevier Masson SAS; 2011;41(12):652–6. | |
dc.source.bibliographicCitation | Suzuki Y, Tokimatsu I, Morinaga Y, Sato Y, Takano K, Kohno K. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clin Chim Acta. Elsevier B.V.; 2015;440:183–7. | |
dc.source.bibliographicCitation | Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients : what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67:1305–10. | |
dc.source.bibliographicCitation | Richardson J, Scheetz M, O’Donnell EP. The association of elevated trough serum vancomycin concentrations with obesity. J Infect Chemother. 2015;21(7):507–11. | |
dc.source.bibliographicCitation | Conil JM, Georges B, Breden A, Ruiz S, Cougot P, Fourcade O, et al. Estimation of glomerular filtration rate to adjust vancomy- cin dosage in critically ill patients : superiority of the Chronic Kidney Disease Epidemiology Collaboration equation ? Anaesth Intensive Care. 2014;42(2):178–84. | |
dc.source.bibliographicCitation | Bourguignon L, Cazaubon Y, Debeurme G, Loue C, Ducher M, Goutelle S. Pharmacokinetics of vancomycin in elderly patients aged over 80 years. Antimicrob Agents Chemother. 2016;1–26 | |
dc.source.instname | instname:Universidad del Rosario | spa |
dc.source.reponame | reponame:Repositorio Institucional EdocUR | spa |
dc.subject | Vancomicina | spa |
dc.subject | Monitoreo de drogas | spa |
dc.subject | Neoplasia | spa |
dc.subject | Hematología | spa |
dc.subject | Vancomicina/farmacología | spa |
dc.subject.ddc | Enfermedades | |
dc.subject.decs | Medicina interna | spa |
dc.subject.decs | Vancomicina | spa |
dc.subject.decs | Neoplasias | spa |
dc.subject.decs | Hematología | spa |
dc.subject.keyword | Vancomycin | eng |
dc.subject.keyword | Drug monitoring | eng |
dc.subject.keyword | Neoplasm | eng |
dc.subject.keyword | Hematology | eng |
dc.subject.keyword | Vamcomycin/pharmacokinetics. | eng |
dc.subject.lemb | Medicina interna | spa |
dc.title | Enfermedad hemato-oncológica y factores asociados con niveles subterapéuticos de vancomicina en un hospital de alta complejidad | spa |
dc.type | masterThesis | eng |
dc.type.hasVersion | info:eu-repo/semantics/acceptedVersion | |
dc.type.spa | Trabajo de grado | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- ParraHernandez-DianaSofia-2017.pdf
- Tamaño:
- 887.9 KB
- Formato:
- Adobe Portable Document Format
- Descripción: